亚胺培南对哌拉西林体外抗铜绿假单胞菌活性的拮抗作用。
Imipenem antagonism of the in vitro activity of piperacillin against Pseudomonas aeruginosa.
作者信息
Bertram M A, Young L S
出版信息
Antimicrob Agents Chemother. 1984 Aug;26(2):272-4. doi: 10.1128/AAC.26.2.272.
Abstract
The MICs of imipenem and piperacillin, alone and in combination, against Pseudomonas aeruginosa were determined in a checkerboard titration microdilution assay. A dramatic, one-way antagonism of imipenem for piperacillin was demonstrated in 28 of the 35 strains examined; antagonism was associated with the induction of a beta-lactamase.
摘要
在棋盘滴定微量稀释试验中测定了亚胺培南和哌拉西林单独及联合使用时对铜绿假单胞菌的最低抑菌浓度（MIC）。在所检测的35株菌株中，有28株显示出亚胺培南对哌拉西林具有显著的单向拮抗作用；这种拮抗作用与β-内酰胺酶的诱导有关。
相似文献
1
Imipenem antagonism of the in vitro activity of piperacillin against Pseudomonas aeruginosa.亚胺培南对哌拉西林体外抗铜绿假单胞菌活性的拮抗作用。
Antimicrob Agents Chemother. 1984 Aug;26(2):272-4. doi: 10.1128/AAC.26.2.272.
2
Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases.由Ro 48 - 1256（一种AmpCβ-内酰胺酶的桥连单环β-内酰胺抑制剂）增强β-内酰胺类药物对铜绿假单胞菌菌株的抗菌活性。
J Antimicrob Chemother. 1997 Sep;40(3):335-43. doi: 10.1093/jac/40.3.335.
3
Determination of synergy by two methods with eight antimicrobial combinations against tobramycin-susceptible and tobramycin-resistant strains of Pseudomonas.采用两种方法对8种抗菌药物组合针对对妥布霉素敏感和耐药的铜绿假单胞菌菌株进行协同作用测定。
Diagn Microbiol Infect Dis. 1987 Feb;6(2):157-64. doi: 10.1016/0732-8893(87)90101-5.
4
Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.由一株产PER-1超广谱β-内酰胺酶的铜绿假单胞菌引起的大鼠实验性肺炎的治疗。
J Antimicrob Chemother. 1999 Jul;44(1):91-7. doi: 10.1093/jac/44.1.91.
5
[Antimicrobial susceptibility of Pseudomonas aeruginosa isolated at Kochi Municipal Central Hospital in the last 3 years].[过去三年在高知县立中央医院分离出的铜绿假单胞菌的抗菌药敏性]
Jpn J Antibiot. 2004 Oct;57(5):438-48.
6
Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.美罗培南、亚胺培南和哌拉西林/他唑巴坦对 1071 株临床分离菌的体外比较活性：一项法国多中心研究。
BMC Infect Dis. 2010 Mar 18;10:72. doi: 10.1186/1471-2334-10-72.
7
Imipenem-induced resistance to antipseudomonal beta-lactams in Pseudomonas aeruginosa.亚胺培南诱导铜绿假单胞菌对抗假单胞菌β-内酰胺类抗生素产生耐药性。
Antimicrob Agents Chemother. 1985 Jul;28(1):41-5. doi: 10.1128/AAC.28.1.41.
8
[Imipenem resistance in Pseudomonas aeruginosa].
Immun Infekt. 1986 Nov;14(6):221-4.
9
Activity of ACHN-490 tested alone and in combination with other agents against Pseudomonas aeruginosa.ACHN-490 单独及与其他药物联合对铜绿假单胞菌的活性。
Antimicrob Agents Chemother. 2011 May;55(5):2463-5. doi: 10.1128/AAC.01390-10. Epub 2011 Jan 31.
10
Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials.美罗培南与其他六种抗菌药物对来自北美研究和临床试验的铜绿假单胞菌分离株的抗菌活性比较。
Clin Infect Dis. 1997 Feb;24 Suppl 2:S191-6. doi: 10.1093/clinids/24.supplement_2.s191.
引用本文的文献
1
Dual beta-lactam treatment: Pros and cons.双β-内酰胺治疗：利弊
Porto Biomed J. 2022 Oct 24;7(5):e189. doi: 10.1097/j.pbj.0000000000000189. eCollection 2022 Sep-Oct.
2
Novel Microdilution Method to Assess Double and Triple Antibiotic Combination Therapy In Vitro.评估体外双重和三联抗生素联合治疗的新型微量稀释法。
Int J Microbiol. 2016;2016:4612021. doi: 10.1155/2016/4612021. Epub 2016 Apr 18.
3
Imipenem and meropenem induced resistance to beta-lactam antibiotics in Pseudomonas aeruginosa.亚胺培南和美罗培南可诱导铜绿假单胞菌对β-内酰胺类抗生素产生耐药性。
Eur J Clin Microbiol Infect Dis. 1994 Apr;13(4):315-8. doi: 10.1007/BF01974609.
4
In vitro activity of imipenem--a review.亚胺培南的体外活性——综述
Eur J Clin Microbiol. 1984 Oct;3(5):456-62. doi: 10.1007/BF02017375.
5
In vitro activity of BMY-28142 against pediatric pathogens, including isolates from cystic fibrosis sputum.BMY-28142对儿科病原体的体外活性，包括来自囊性纤维化痰液的分离株。
Antimicrob Agents Chemother. 1985 Jul;28(1):58-63. doi: 10.1128/AAC.28.1.58.
6
Imipenem-induced resistance to antipseudomonal beta-lactams in Pseudomonas aeruginosa.亚胺培南诱导铜绿假单胞菌对抗假单胞菌β-内酰胺类抗生素产生耐药性。
Antimicrob Agents Chemother. 1985 Jul;28(1):41-5. doi: 10.1128/AAC.28.1.41.
7
Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.亚胺培南/西司他丁。对其抗菌活性、药代动力学特性及治疗效果的综述。
Drugs. 1987 Mar;33(3):183-241. doi: 10.2165/00003495-198733030-00001.
8
Antibacterial therapy in patients with malignancies.恶性肿瘤患者的抗菌治疗。
Cancer Metastasis Rev. 1987;5(3):271-93. doi: 10.1007/BF00047001.
9
[A comparative review of combination therapy: 2 beta-lactams versus beta-lactam plus aminoglycoside].联合治疗的比较综述：两种β-内酰胺类药物与β-内酰胺类药物加氨基糖苷类药物的对比
Infection. 1987;15 Suppl 4:S158-67. doi: 10.1007/BF01645863.
10
Synergism of the combinations of imipenem plus ciprofloxacin and imipenem plus amikacin against Pseudomonas aeruginosa and other bacterial pathogens.亚胺培南联合环丙沙星以及亚胺培南联合阿米卡星对铜绿假单胞菌和其他细菌病原体的协同作用。
Antimicrob Agents Chemother. 1987 Apr;31(4):632-4. doi: 10.1128/AAC.31.4.632.
本文引用的文献
1
Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method.具有抗假单胞菌活性的氨基糖苷类药物与头孢菌素之间的协同作用：相互作用指数和杀菌曲线法
Antimicrob Agents Chemother. 1982 Nov;22(5):743-52. doi: 10.1128/AAC.22.5.743.
2
Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability.N-甲酰亚胺硫霉素对革兰氏阳性和革兰氏阴性需氧及厌氧菌的体外比较活性及其β-内酰胺酶稳定性
Antimicrob Agents Chemother. 1982 Jan;21(1):180-7. doi: 10.1128/AAC.21.1.180.
3
MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities.MK0787（N-亚胺甲酰硫霉素）：体内外活性评估
Antimicrob Agents Chemother. 1980 Jun;17(6):993-1000. doi: 10.1128/AAC.17.6.993.
4
A comparison of the antibacterial activities of N-formimidoyl thienamycin (MK0787) with those of other recently developed beta-lactam derivatives.N-甲酰亚胺基硫霉素（MK0787）与其他近期研发的β-内酰胺衍生物抗菌活性的比较。
Antimicrob Agents Chemother. 1982 Aug;22(2):302-7. doi: 10.1128/AAC.22.2.302.
5
Novel resistance selected by the new expanded-spectrum cephalosporins: a concern.新型广谱头孢菌素所选择的新型耐药性：一个值得关注的问题。
J Infect Dis. 1983 Mar;147(3):585-9. doi: 10.1093/infdis/147.3.585.
6
Clinical trial of piperacillin with acquisition of resistance by Pseudomonas and clinical relapse.哌拉西林治疗伴有铜绿假单胞菌耐药获得及临床复发情况的临床试验
Antimicrob Agents Chemother. 1980 Jul;18(1):167-70. doi: 10.1128/AAC.18.1.167.
7
Piperacillin therapy for serious bacterial infections.
Am J Med. 1980 Aug;69(2):255-61. doi: 10.1016/0002-9343(80)90386-1.
8
Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections.哌拉西林单药治疗与羧苄青霉素 - 氨基糖苷类联合治疗方案在严重细菌感染经验性治疗中的前瞻性随机试验。
Antimicrob Agents Chemother. 1983 Sep;24(3):388-93. doi: 10.1128/AAC.24.3.388.
9
Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future.新型β-内酰胺类抗生素治疗期间耐药性的出现：诱导性β-内酰胺酶的作用及对未来的影响。
Rev Infect Dis. 1983 Jul-Aug;5(4):639-48. doi: 10.1093/clinids/5.4.639.
10
In-vitro antagonism by N-formimidoyl thienamycin and cefoxitin of second and third generation cephalosporins in Aeromonas hydrophila and Serratia marcescens.N-甲酰亚胺硫霉素和头孢西丁对嗜水气单胞菌和粘质沙雷氏菌中第二代和第三代头孢菌素的体外拮抗作用。
J Antimicrob Chemother. 1983 Apr;11(4):311-8. doi: 10.1093/jac/11.4.311.
Zotero 插件